Turning profits with Dr. Clay Siegall

Recently, Dr. Clay Siegall was interviewed by Inspirely.com about his company, Seattle Genetics, and how he first made a break in the biotechnology industry. In this interview, Dr. Clay Siegall discusses how he acquired his first customer, what inspired him to start this company and join this industry, and how long it took for his business to turn a profit. He also discusses what he thinks defines a successful businessman and how he thinks that definition applies to himself.

 

Dr. Siegall helped co-found Seattle Genetics in 1998, and currently, serves as President and Chief Executive Officer, while also maintaining a position as Chairman of the Board of Directors. During his time with Seattle Genetics, Dr. Siegall has helped developed a number of antibody-based cancer therapies. These include treatments such as ADCETRIS (brentuximab vedotin), which is currently in the process of accelerated approval by the FDA in 2011.

 

Dr. Siegall has also managed to help secure more than $675 million in capital through both public and private financing. Allowing Seattle Genetics plenty of room to grow and continue their research uninhibited by monetary constraints. He believes that success is dependent upon an Entrepreneurs desire and willingness to consistently learn. As without development an Entrepreneur can become stagnant and be lacking in vision.

 

Before founding Seattle Genetics, Dr. Siegall worked with the Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997, and before that with the National Cancer Institute and the National Institute of Health from 1988 to 1991. Graduating from the University of Maryland with a Bachelors Degree in Zoology, Dr. Siegall received his Ph.D. in Genetics from George Washington University.

 

Currently, Dr. Siegall serves on the Board of Directors for Alder BioPharmaceuticals, which is a private biotech company. He also holds 70 publications and 15 patents to his name, making Dr. Siegall a recognizable and influential name inside the biotech industry.

 

Leave a Reply